Form 8-K - Current report:
SEC Accession No. 0000950170-23-014788
Filing Date
2023-04-26
Accepted
2023-04-26 16:06:24
Documents
14
Period of Report
2023-04-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20230426.htm   iXBRL 8-K 58747
2 EX-99.1 vktx-ex99_1.htm EX-99 268360
3 GRAPHIC img201808844_0.jpg GRAPHIC 13142
  Complete submission text file 0000950170-23-014788.txt   487122

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vktx-20230426_lab.xml EX-101.LAB 17757
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vktx-20230426.xsd EX-101.SCH 2492
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vktx-20230426_pre.xml EX-101.PRE 11130
8 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20230426_htm.xml XML 4719
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 23849730
SIC: 2834 Pharmaceutical Preparations